(Total Views: 496)
Posted On: 12/20/2022 6:15:16 PM
Post# of 148870
Madrigal Pharma…..
“ The company tested its treatment in more than 950 patients with nonalcoholic steatohepatitis, or NASH. NASH is a progressive disease that causes liver inflammation called fibrosis. So far, the field has been marked by high-profile failures, and there are no approved treatments.
After a year, 30% of patients at the highest dose experienced at least a two-point improvement in their symptoms on an eight-point scale. Meanwhile, their fibrosis didn't worsen.
Another measure looked at fibrosis, which is measured in five stages. There, 26% of patients showed an improvement of at least one stage in fibrosis while their symptoms didn't progress.
The Food and Drug Administration requires NASH drugs to meet one of these bars to gain approval.”
So how do we stack up compared to these results?
“ The company tested its treatment in more than 950 patients with nonalcoholic steatohepatitis, or NASH. NASH is a progressive disease that causes liver inflammation called fibrosis. So far, the field has been marked by high-profile failures, and there are no approved treatments.
After a year, 30% of patients at the highest dose experienced at least a two-point improvement in their symptoms on an eight-point scale. Meanwhile, their fibrosis didn't worsen.
Another measure looked at fibrosis, which is measured in five stages. There, 26% of patients showed an improvement of at least one stage in fibrosis while their symptoms didn't progress.
The Food and Drug Administration requires NASH drugs to meet one of these bars to gain approval.”
So how do we stack up compared to these results?
(2)
(0)Scroll down for more posts ▼
